Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review

Baudel, Jean Luc; Vigneron, C.; Pras-Landre, Veronique; Joffre, Jérémie; Marjot, Frédéric; Ait‐Oufella, Hafid; Bigé, Naïke; Maury, Éric; Guidet, Bertrand; Fain, Olivier; Mékinian, A.

doi:10.1007/s10067-019-04832-7

Cited by 34 publications

(33 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these data are preliminary, and outcomes of clinical trials are awaited [ 156 ]. Transfusion-related acute lung injury (TRALI) is a rare complication of IVIg therapy [ 157 ], and it has even been reported with convalescence plasma therapy, too [ 158 ].…”

Section: Targeting Thrombosis In Severe Covid-19mentioning

confidence: 99%

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

2020

View full text Add to dashboard Cite

The pathogenesis of Coronavirus disease 2019 (COVID-19) is gradually being comprehended. A high number of thrombotic episodes are reported, along with the mortality benefits of heparin. COVID-19 can be viewed as a prothrombotic disease. We overviewed the available evidence to explore this possibility. We identified various histopathology reports and clinical case series reporting thromboses in COVID-19. Also, multiple coagulation markers support this. COVID-19 can be regarded as a risk factor for thrombosis. Applying the principles of Virchow's triad, we described abnormalities in the vascular endothelium, altered blood flow, and platelet function abnormalities that lead to venous and arterial thromboses in COVID-19. Endothelial dysfunction, activation of the renin-angiotensin-aldosterone system (RAAS) with the release of procoagulant plasminogen activator inhibitor (PAI-1), and hyperimmune response with activated platelets seem to be significant contributors to thrombogenesis in COVID-19. Stratifying risk of COVID-19 thromboses should be based on age, presence of comorbidities, D-dimer, CT scoring, and various blood cell ratios. Isolated heparin therapy may not be sufficient to combat thrombosis in this disease. There is an urgent need to explore newer avenues like activated protein C, PAI-1 antagonists, and tissue plasminogen activators (tPA). These should be augmented with therapies targeting RAAS, antiplatelet drugs, repurposed antiinflammatory, and antirheumatic drugs.

show abstract

Section: Targeting Thrombosis In Severe Covid-19mentioning

confidence: 99%

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

2020

View full text Add to dashboard Cite

show abstract

“…Although rare, there are some case reports of TRALI after IVIG in the published literature, and they were reviewed recently by Baudel et al (5) To our knowledge there are just three other cases of TRALI described in the pediatric population, (5,6) and this is the first report of a child that received later doses of IVIG after experiencing TRALI.…”

Section: ❚ Discussionmentioning

confidence: 85%

Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient

Pegler

Castro

Pastorino

et al. 2020

Einstein (São Paulo)

View full text Add to dashboard Cite

Case report of a patient with an immunodeficiency who demands regular replacement of intravenous immunoglobulin. She presented an episode of transfusion-related acute lung injury shortly after using an immunoglobulin product different than the one she usually received. The patient evolved with respiratory changes (hypoxia, dyspnea, change in pulmonary auscultation) minutes after the end of the infusion, and received non-invasive respiratory support. She was discharged after 36 hours with good outcome. The patient achieved full recovery, showing no further reactions in subsequent immunoglobulin infusions (no longer receiving the product that was used when she had the episode of transfusion-related acute lung injury). Although rare, this reaction is potentially serious and has no specific treatment other than supportive therapy. The literature is scarce regarding the risk of recurrence. The decision on whether to proceed with immunoglobulin therapy after this adverse effect should be analyzed individually, assessing the possible risks and benefits for the patient.

show abstract

“…IVIG is also thought to be a cause of cytokine storm, greatly influencing variation and balance in individuals. Although IVIG is a popular and powerful therapy for many autoimmune diseases and KD, it has been reported to have many side effects [51][52][53][54][55] . In this study, we used ELISA to monitor the variations of KD protein biomarkers.…”

Section: Discussionmentioning

confidence: 99%

Serum proteins may facilitate the identification of Kawasaki disease and promote in vitro neutrophil infiltration

Huang

Weng

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Kawasaki disease (KD) usually affects the children younger than 5 years of age and subsequently causes coronary artery lesions (CALs) without timely identification and treatment. Developing a robust and fast prediction method may facilitate the timely diagnosis of KD, significantly reducing the risk of CALs in KD patients. The levels of inflammatory serum proteins dramatically vary during the onsets of many immune diseases, including in KD. However, our understanding of their pathogenic roles in KD is behind satisfaction. The purpose of this study was to evaluate candidate diagnostic serum proteins and the potential mechanism in KD using iTRAQ gel-free proteomics. We enrolled subjects and conducted iTRAQ gel-free proteomics to globally screen serum proteins followed by specific validation with ELISA. Further in vitro leukocyte trans-endothelial model was also applied to investigate the pathogenesis roles of inflammatory serum proteins. We identified six KD protein biomarkers, including Protein S100-A8 (S100A8), Protein S100-A9 (S100A9), Protein S100-A12 (S100A12), Peroxiredoxin-2 (PRDX2), Neutrophil defensin 1 (DEFA1) and Alpha-1-acid glycoprotein 1 (ORM1). They enabled us to develop a high-performance KD prediction model with an auROC value of 0.94, facilitating the timely identification of KD. Further assays concluded that recombinant S100A12 protein treatment activated neutrophil surface adhesion molecules responsible for adhesion to endothelial cells. Therefore, S100A12 promoted both freshly clinically isolated neutrophils and neutrophil-like cells to infiltrate through the endothelial layer in vitro. Finally, the antibody against S100A12 may attenuate the infiltration promoted by S100A12. Our result demonstrated that evaluating S100A8, S100A9, S100A12, PRDX2, DEFA1 and ORM1 levels may be a good diagnostic tool of KD. Further in vitro study implied that S100A12 could be a potential therapeutic target for KD.

show abstract

Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review

Cited by 34 publications

References 30 publications

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad

Transfusion-related acute lung injury associated to intravenous immunoglobulin infusion in a pediatric patient

Serum proteins may facilitate the identification of Kawasaki disease and promote in vitro neutrophil infiltration

Contact Info

Product

Resources

About